Prolog Ventures

Prolog Ventures is a venture capital firm based in Clayton, Missouri, established in 2000. The firm specializes in investments in startups and early-stage companies, primarily focusing on the life sciences and related information technology sectors. Prolog Ventures targets traditional healthcare opportunities as well as emerging fields such as nutrition, wellness, and green technology. Additionally, it invests in consumer health and wellness companies that offer innovative products and technologies in fast-moving consumer goods markets, including personal care, functional foods and beverages, medical foods, dietary supplements, and household care. The firm emphasizes investments in products that enhance the health and well-being of both people and companion animals through proprietary ingredients, formulations, and delivery technologies. Prolog Ventures primarily operates within North America.

Lindsay Freeman Avagliano

Senior Associate

Daniel Broderick

Venture Partner

Greg Johnson

Founder and Managing Director

Ilya Nykin

Co-Founder and Managing Director

Rosenberg, Robert M.

Managing Director

Teddy Shalon

General Partner

Gregory Johnson Ph.D

Co-Founder and Managing Director

73 past transactions

Benson Hill

Series D in 2020
Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.

CleanSlate UV

Series A in 2020
CleanSlate UV allows staff, patients and visitors to sanitize their personal items (such as phones, tablets and badges) while they wash or sanitize their hands. This helps improve hand hygiene and reduce the risk of hospital acquired infections. Its mission is simple: eliminate pathogens on mobile devices through the use of effective and easy-to-use UV products. We do this by designing technologies that people will actually use, backed by science reflective of real-world conditions. CleanSlate harness the power of UV light to kill the most dangerous bacteria without damaging expensive touch screens.

Covercress

Venture Round in 2020
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

Kinnos

Series A in 2020
Kinnos Inc. is a biotechnology company based in Brooklyn, New York, that specializes in improving disinfection practices through innovative color technology. Founded in 2014, the company manufactures a powdered additive called Highlight, which enhances the visibility of disinfectants, ensuring thorough cleaning and compliance during disinfection processes. Highlight provides real-time color-change feedback, allowing users to see where disinfectants have been applied, which helps prevent disease outbreaks on various surfaces. In addition to Highlight, Kinnos also offers Highlight Wipes, a dispensing machine for wipes, and Highlight Powder, another form of their disinfectant additive. The company's mission is to empower individuals to disinfect with confidence and to enhance public health through effective and visible disinfection.

Kinnos

Venture Round in 2020
Kinnos Inc. is a biotechnology company based in Brooklyn, New York, that specializes in improving disinfection practices through innovative color technology. Founded in 2014, the company manufactures a powdered additive called Highlight, which enhances the visibility of disinfectants, ensuring thorough cleaning and compliance during disinfection processes. Highlight provides real-time color-change feedback, allowing users to see where disinfectants have been applied, which helps prevent disease outbreaks on various surfaces. In addition to Highlight, Kinnos also offers Highlight Wipes, a dispensing machine for wipes, and Highlight Powder, another form of their disinfectant additive. The company's mission is to empower individuals to disinfect with confidence and to enhance public health through effective and visible disinfection.

bioClarity

Venture Round in 2019
BioClarity is dedicated to solving the skincare needs of young adults by fusing nature and science to create the next generation of acne fighting products.

SchoolCare

Series C in 2019
SchoolCare is a digital health platform dedicated to enhancing pediatric healthcare in K-12 public schools. By providing free health technology, it assists school nurses in delivering effective care and ensuring student safety. The platform captures essential health information, including student medical charts, medications, and immunizations, while facilitating communication between schools, families, and healthcare providers. This connectivity allows for timely alerts about health events and supports the efficient operation of public school health programs. By addressing gaps in traditional care coordination, SchoolCare aims to improve health outcomes for children, ensuring that they receive consistent and comprehensive care throughout their school experience.

Covercress

Venture Round in 2018
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

TOMA Biosciences

Series C in 2018
TOMA Biosciences, Inc. is a genomics company based in Foster City, California, focused on developing reagent kits and cancer testing technologies that assist laboratories and researchers in identifying genomic changes in tumors. The company offers TOMA OS-Seq, an oncology-focused gene analysis solution that leverages advanced next-generation sequencing technology to detect clinically significant alterations in tumor DNA. This information is crucial for physicians to optimize treatment strategies for cancer patients by providing insights into the genomic errors present in their tumors. TOMA Biosciences serves a wide range of clients, including laboratories, hospital systems, and research institutions globally, and aims to improve clinical outcomes through its innovative testing solutions. The company has been operational since its incorporation in 2011.

Spindrift

Series B in 2018
Spindrift Beverage Co., Inc., founded in 2010 and based in Newton, Massachusetts, specializes in producing unsweetened sparkling beverages made with real squeezed fruit. The company offers a range of drinks that combine triple-filtered sparkling water with authentic fruit flavors, such as lemon, raspberry lime, and strawberry, without any artificial sweeteners. Spindrift aims to provide consumers with refreshing beverages that promote a healthy and active lifestyle through the use of real ingredients.

Benson Hill

Series B in 2017
Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.

Spindrift

Series B in 2017
Spindrift Beverage Co., Inc., founded in 2010 and based in Newton, Massachusetts, specializes in producing unsweetened sparkling beverages made with real squeezed fruit. The company offers a range of drinks that combine triple-filtered sparkling water with authentic fruit flavors, such as lemon, raspberry lime, and strawberry, without any artificial sweeteners. Spindrift aims to provide consumers with refreshing beverages that promote a healthy and active lifestyle through the use of real ingredients.

Covercress

Venture Round in 2017
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

SchoolCare

Series B in 2016
SchoolCare is a digital health platform dedicated to enhancing pediatric healthcare in K-12 public schools. By providing free health technology, it assists school nurses in delivering effective care and ensuring student safety. The platform captures essential health information, including student medical charts, medications, and immunizations, while facilitating communication between schools, families, and healthcare providers. This connectivity allows for timely alerts about health events and supports the efficient operation of public school health programs. By addressing gaps in traditional care coordination, SchoolCare aims to improve health outcomes for children, ensuring that they receive consistent and comprehensive care throughout their school experience.

SchoolCare

Debt Financing in 2016
SchoolCare is a digital health platform dedicated to enhancing pediatric healthcare in K-12 public schools. By providing free health technology, it assists school nurses in delivering effective care and ensuring student safety. The platform captures essential health information, including student medical charts, medications, and immunizations, while facilitating communication between schools, families, and healthcare providers. This connectivity allows for timely alerts about health events and supports the efficient operation of public school health programs. By addressing gaps in traditional care coordination, SchoolCare aims to improve health outcomes for children, ensuring that they receive consistent and comprehensive care throughout their school experience.

Intellicyt

Venture Round in 2015
IntelliCyt Corporation specializes in the development of high-throughput cell- and bead-based screening solutions tailored for the life sciences sector, particularly in drug discovery, antibody development, and immunology. Founded in 2006 and based in Albuquerque, New Mexico, the company offers a comprehensive iQue Screener platform that integrates instrumentation, software, and reagents to facilitate high-content multiplex analysis of samples in liquid suspension. This platform is complemented by ForeCyt software for data visualization and analysis, as well as MultiCyt screening kits designed for use with iQue Screeners. IntelliCyt’s innovative technologies significantly enhance the efficiency and cost-effectiveness of detecting and measuring cells and beads, addressing critical needs in pharmaceutical and biotechnology laboratories globally. As a subsidiary of Sartorius AG, IntelliCyt continues to lead in providing solutions that meet the demands of modern life sciences research while ensuring rapid and relevant results in various applications, including phenotypic small molecule drug discovery and in vitro toxicology.

Veran Medical Technologies

Venture Round in 2015
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Benson Hill

Series A in 2015
Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.

NeuroLutions

Venture Round in 2015
NeuroLutions Inc. is a company based in St. Louis, Missouri, focused on developing brain-computer interface (BCI) devices aimed at restoring functions for patients disabled due to neurological injuries, particularly stroke survivors. Founded in 2007, NeuroLutions employs non-invasive electroencephalography (EEG) technology to capture brain activity without the need for implanted electrodes. The EEG data is wirelessly transmitted to a tablet, where it is analyzed to interpret the patient's intended muscle movements. This innovative approach enables users to facilitate muscle re-education and helps maintain or improve their range of motion, thereby enhancing rehabilitation outcomes for individuals with movement impairments.

Covercress

Series A in 2015
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

Veniti

Series C in 2015
VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

Veran Medical Technologies

Venture Round in 2014
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

AirXpanders

Series E in 2014
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Veran Medical Technologies

Debt Financing in 2014
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Spindrift

Venture Round in 2014
Spindrift Beverage Co., Inc., founded in 2010 and based in Newton, Massachusetts, specializes in producing unsweetened sparkling beverages made with real squeezed fruit. The company offers a range of drinks that combine triple-filtered sparkling water with authentic fruit flavors, such as lemon, raspberry lime, and strawberry, without any artificial sweeteners. Spindrift aims to provide consumers with refreshing beverages that promote a healthy and active lifestyle through the use of real ingredients.

Singulex

Series G in 2013
Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

EndoStim

Series D in 2013
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

Veniti

Series B in 2013
VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

AirXpanders

Series E in 2013
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Intellicyt

Venture Round in 2013
IntelliCyt Corporation specializes in the development of high-throughput cell- and bead-based screening solutions tailored for the life sciences sector, particularly in drug discovery, antibody development, and immunology. Founded in 2006 and based in Albuquerque, New Mexico, the company offers a comprehensive iQue Screener platform that integrates instrumentation, software, and reagents to facilitate high-content multiplex analysis of samples in liquid suspension. This platform is complemented by ForeCyt software for data visualization and analysis, as well as MultiCyt screening kits designed for use with iQue Screeners. IntelliCyt’s innovative technologies significantly enhance the efficiency and cost-effectiveness of detecting and measuring cells and beads, addressing critical needs in pharmaceutical and biotechnology laboratories globally. As a subsidiary of Sartorius AG, IntelliCyt continues to lead in providing solutions that meet the demands of modern life sciences research while ensuring rapid and relevant results in various applications, including phenotypic small molecule drug discovery and in vitro toxicology.

Akermin

Venture Round in 2013
Akermin is based in St. Louis, Missouri, and was formed in 2004 to commercialize breakthrough stabilized enzyme technology invented at Saint Louis University. In 2008, Akermin demonstrated its prototype of a fully functioning biofuel cell operating on methanol fuel and using stabilized laccase to replace the metal catalyst in conventional cathodes. Commercial applications in wireless sensors and military uses are their primary focus. Development for the use of stabilized enzymes in the food processing, biofuels, chemical, and pharmaceutical industries is under way.

EndoStim

Series C in 2013
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

AirXpanders

Series D in 2012
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Zeel

Seed Round in 2012
Zeel is a company that provides on-demand massage services, allowing customers to book high-quality massages from licensed and vetted therapists at their homes, hotels, workplaces, or events. Founded in 2012 and launching its app in 2013, Zeel aims to disrupt the massage industry by offering convenience and flexibility, enabling bookings as soon as one hour in advance or up to a month ahead. Customers can choose from various massage types, including Swedish, deep tissue, prenatal, sports, and couples massages, all at a set price that includes tax and tips. The therapists are thoroughly vetted, licensed, insured, and trained to ensure top-notch customer service. In 2013, Zeel introduced Massage Zeelot, a subscription service that provides customers with at least one in-home massage per month at a discounted rate, along with a professional-grade massage table for personal use.

Singulex

Series F in 2012
Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

AirXpanders

Series D in 2012
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

The Nest Collective

Venture Round in 2012
The Nest Collective, Inc. produces organic food and snacks for babies, toddlers, and kids. The company was incorporated in 2008 and is based in Emeryville, California.

EndoStim

Venture Round in 2011
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Veniti

Series A in 2011
VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

EndoStim

Series B in 2010
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

Akermin

Series B in 2010
Akermin is based in St. Louis, Missouri, and was formed in 2004 to commercialize breakthrough stabilized enzyme technology invented at Saint Louis University. In 2008, Akermin demonstrated its prototype of a fully functioning biofuel cell operating on methanol fuel and using stabilized laccase to replace the metal catalyst in conventional cathodes. Commercial applications in wireless sensors and military uses are their primary focus. Development for the use of stabilized enzymes in the food processing, biofuels, chemical, and pharmaceutical industries is under way.

Plum Organics

Series B in 2009
Plum Organics is a prominent brand specializing in organic baby food and toddler snacks, focused on promoting healthy eating from an early age. The company offers a diverse range of culinary-inspired baby foods in three developmental stages, ensuring optimal nutrition through gentle cooking methods. Plum Organics emphasizes sustainability by prioritizing ingredient sourcing and packaging choices that minimize environmental impact. Their product line includes pouch purees, finger foods, and lunchbox snacks, designed to provide parents with nutritious and convenient meal solutions for their children. By combining great taste with health-conscious ingredients, Plum Organics aims to support families in fostering lifelong healthy eating habits.

Divergence

Series C in 2009
Divergence is a research and development company focused on creating effective and environmentally sustainable methods for controlling parasites and pests, particularly parasitic nematodes. These roundworms are significant agricultural pests, inflicting billions of dollars in damage to various crops, such as soybeans, corn, cotton, strawberries, and bananas. Additionally, some nematodes are responsible for serious human diseases, including hookworm, whipworm, and roundworm infections, as well as filarial infections that lead to lymphatic filariasis and onchocerciasis. By developing innovative genes and molecules, Divergence aims to address the challenges posed by these harmful organisms in both agricultural and medical contexts.
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Asoyia

Venture Round in 2008
Asoyia, LLC produces soybeans and soybean oil.

CS-Keys

Series A in 2008
CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.

Akermin

Series A in 2007
Akermin is based in St. Louis, Missouri, and was formed in 2004 to commercialize breakthrough stabilized enzyme technology invented at Saint Louis University. In 2008, Akermin demonstrated its prototype of a fully functioning biofuel cell operating on methanol fuel and using stabilized laccase to replace the metal catalyst in conventional cathodes. Commercial applications in wireless sensors and military uses are their primary focus. Development for the use of stabilized enzymes in the food processing, biofuels, chemical, and pharmaceutical industries is under way.

Chlorogen

Venture Round in 2007
Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.

Singulex

Series D in 2007
Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

Dreamerz Foods

Series B in 2007
Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.

Natural Dentist

Series B in 2007
The Natural Dentist, Inc., founded in 1995 and based in Medford, Massachusetts, specializes in manufacturing oral care products, including mouth rinses and toothpastes. The company, which was previously known as Woodstock Natural Products Inc. before rebranding in 2005, provides its products through various retail channels, including physical stores and online platforms. In 2010, The Natural Dentist was acquired by Revive Personal Products Company. The company is part of a broader portfolio that includes over-the-counter consumer healthcare brands, reflecting its commitment to promoting oral health and hygiene.

Attune Foods

Series B in 2007
Attune Foods, Inc. offers probiotic wellness bars. It offers wellness bars in various flavors, including dark chocolate, chocolate crisp, mint chocolate, and blueberry vanilla, as well as chewy chocolate, peanut butter and chocolate, mango peach, wild berry, strawberry bliss, and lemon crème. Attune Foods, Inc. was founded in 2006 and is headquartered in San Francisco, California.

AirXpanders

Series A in 2007
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

AirXpanders

Venture Round in 2006
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Dreamerz Foods

Series A in 2006
Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.

Natural Dentist

Series B in 2006
The Natural Dentist, Inc., founded in 1995 and based in Medford, Massachusetts, specializes in manufacturing oral care products, including mouth rinses and toothpastes. The company, which was previously known as Woodstock Natural Products Inc. before rebranding in 2005, provides its products through various retail channels, including physical stores and online platforms. In 2010, The Natural Dentist was acquired by Revive Personal Products Company. The company is part of a broader portfolio that includes over-the-counter consumer healthcare brands, reflecting its commitment to promoting oral health and hygiene.

Travanti Pharma

Series B in 2006
Travanti Pharma is a privately held company that focuses on the design, development, and marketing of innovative drug delivery platforms aimed at enhancing the safety, compliance, effectiveness, and ease of medication administration. The company's technology includes an electronic drug delivery system that employs controlled low-level electrical energy to safely transport drugs through the skin or other areas of the body. Additionally, Travanti Pharma offers a wearable electronic disposable drug delivery system, which is a portable and disposable solution for transdermal medication delivery. Through these advanced technologies, Travanti Pharma seeks to improve patient outcomes and streamline the drug delivery process.

Singulex

Series C in 2006
Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

EraGen Biosciences

Series A in 2006
EraGen Biosciences, Inc. is a biotechnology company based in Madison, Wisconsin, that specializes in developing, manufacturing, and marketing molecular reagent products and software for research and clinical testing markets. The company provides molecular diagnostic assays designed for the early detection and monitoring of cancer, genetic disorders, infectious diseases, and other genetic-based conditions. Its product offerings include molecular diagnostic tests, analyte specific reagents, in vitro diagnostic reagents, and research use only reagents. Additionally, EraGen Biosciences offers MultiCode-PLx and MultiCode-RTx Analysis Software, which enable users to create customized templates for assay layouts and conduct quantitative and qualitative analyses, respectively. The company primarily serves clinical laboratories and medical researchers, distributing its products across the United States and Canada. Founded in 1994 as Sulfonics, Inc., it adopted the name EraGen Biosciences, Inc. in 1999.

Akermin

Series A in 2005
Akermin is based in St. Louis, Missouri, and was formed in 2004 to commercialize breakthrough stabilized enzyme technology invented at Saint Louis University. In 2008, Akermin demonstrated its prototype of a fully functioning biofuel cell operating on methanol fuel and using stabilized laccase to replace the metal catalyst in conventional cathodes. Commercial applications in wireless sensors and military uses are their primary focus. Development for the use of stabilized enzymes in the food processing, biofuels, chemical, and pharmaceutical industries is under way.

Kereos

Series B in 2005
Kereos, Inc., a biotechnology company, develops targeted molecular imaging agents and therapeutics to detect and treat cancer and cardiovascular disease. The company offers KI-0001, a magnetic resonance imaging (MRI) agent for tumor detection that finds tumors and highlights growing regions in the tumor margin; and KI-100X, a targeted chemotherapeutics for solid tumors, which reduces angiogenesis in tumor and atherosclerosis models, as well as inhibits tumor growth. It also provides KI-0002, an MRI agent for cardiovascular disease detection via an undisclosed biomarker; KI-1004, an anti-restenotic that inhibits restenosis while preserving re-endotheliazation in angioplasty models; and KM-4419, a targeted chemotherapeutic for solid tumors that synergizes with several chemotherapeutics in blocking tumor growth and increasing survival. In addition, the company works with pharmaceutical and imaging companies for the development and commercialization of cardiovascular disease MRI agents, as well as development of molecular imaging systems. Kereos, Inc. was founded in 1999 and is based in St. Louis, Missouri.

Chlorogen

Series B in 2005
Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.

Quick Study Radiology

Series C in 2005
Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.

Travanti Pharma

Series A in 2005
Travanti Pharma is a privately held company that focuses on the design, development, and marketing of innovative drug delivery platforms aimed at enhancing the safety, compliance, effectiveness, and ease of medication administration. The company's technology includes an electronic drug delivery system that employs controlled low-level electrical energy to safely transport drugs through the skin or other areas of the body. Additionally, Travanti Pharma offers a wearable electronic disposable drug delivery system, which is a portable and disposable solution for transdermal medication delivery. Through these advanced technologies, Travanti Pharma seeks to improve patient outcomes and streamline the drug delivery process.

Zystor

Series A in 2004
ZyStor Therapeutics, Inc. is a privately-held biotechnology company focused on developing enzyme replacement therapies for lysosomal storage diseases. The company specializes in creating innovative replacement technologies that enhance the delivery of therapeutics designed to substitute for missing lysosomal enzymes. These therapies aim to address the needs of patients suffering from genetic disorders characterized by lysosomal storage dysfunction.

Quick Study Radiology

Series C in 2004
Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.

Efficas

Series A in 2004
Efficas, Inc., based in Boulder, Colorado, is a health science and technology company that specializes in the research, development, and commercialization of products aimed at nutritional management of the immune system for both humans and pets. Founded in 2003, the company offers EFFICAS CARE, a berry-flavored non-prescription medical food designed to assist in the dietary management of asthma and related allergies. Efficas focuses on creating effective solutions that work with the body's natural systems, providing safe and significant health benefits to patients suffering from asthma and allergic conditions.

Divergence

Venture Round in 2004
Divergence is a research and development company focused on creating effective and environmentally sustainable methods for controlling parasites and pests, particularly parasitic nematodes. These roundworms are significant agricultural pests, inflicting billions of dollars in damage to various crops, such as soybeans, corn, cotton, strawberries, and bananas. Additionally, some nematodes are responsible for serious human diseases, including hookworm, whipworm, and roundworm infections, as well as filarial infections that lead to lymphatic filariasis and onchocerciasis. By developing innovative genes and molecules, Divergence aims to address the challenges posed by these harmful organisms in both agricultural and medical contexts.

Chlorogen

Series A in 2003
Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.

Divergence

Venture Round in 2002
Divergence is a research and development company focused on creating effective and environmentally sustainable methods for controlling parasites and pests, particularly parasitic nematodes. These roundworms are significant agricultural pests, inflicting billions of dollars in damage to various crops, such as soybeans, corn, cotton, strawberries, and bananas. Additionally, some nematodes are responsible for serious human diseases, including hookworm, whipworm, and roundworm infections, as well as filarial infections that lead to lymphatic filariasis and onchocerciasis. By developing innovative genes and molecules, Divergence aims to address the challenges posed by these harmful organisms in both agricultural and medical contexts.

Inoveon

Series B in 2002
Inoveon Corporation is a medical services company based in Oklahoma City, Oklahoma, focused on providing solutions for the detection, staging, and monitoring of eye diseases, specifically diabetic retinopathy, macular degeneration, and glaucoma. Founded in 1997, Inoveon offers advanced technologies, including iScan, which assesses diabetic retinopathy and macular edema, and the INOVEON System, designed to enhance compliance rates among physician groups for managing these conditions. As a subsidiary of Ifa Systems Ag since 2010, Inoveon aims to support healthcare providers in delivering quality care to patients with eye-related diseases, ultimately working to preserve eyesight.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.